Question explored with the scientific record
Conversation so far
- 1 what about promising trials on cancer with fenbendazole
- 2 i meant fenbendazole in combo with ivermectin — not in lieu of chemo but as a complement and taken at nontoxic doses
Answered on this page ↓
i meant fenbendazole in combo with ivermectin — not in lieu of chemo but as a complement and taken at nontoxic doses
The combination you're describing has not been tested in people with cancer. Not one trial, not one case series in front of me.
Ivermectin has real preclinical anticancer signals. It blocks drug-resistance pumps, shuts down AKT/mTOR and Wnt signaling, and kills cancer stem-like cells in dishes, with synergy against leukemia cells alongside standard chemo drugs [2]. A 2025 colorectal paper flagged it as a possible adjunct to immunotherapy based on gene-expression modeling [1]. That is a hypothesis, not an outcome. Fenbendazole's human record is the liver injury case I already gave you, and nothing in this retrieval adds a human cancer trial for either drug, alone or together.
The only record that puts fenbendazole and ivermectin in the same sentence is a 1991 horse-deworming study [3] and a 2004 soil-nematode toxicity study [4]. Neither is cancer. Neither is a person. That is the entire combined evidence base here.
What the combination would actually mean for a patient on chemo: unknown drug-drug interactions, unknown liver and marrow toxicity stacking on top of chemo's own, and no data on whether it helps or hurts the chemo. The mechanism story is plausible. Plausible is not tested.
| Question | What the evidence shows |
|---|---|
| Human cancer trial, fenbendazole + ivermectin | None in this retrieval |
| Ivermectin anticancer mechanism | Preclinical only [2] |
| Ivermectin as immunotherapy adjunct | Modeling prediction, colorectal [1] |
| Combined human safety data | None |
My call: do not add this combination to chemo outside a supervised trial. The mechanism is interesting; the human evidence is absent and the interaction risk is real. Confidence: moderate that no human combination data exists in this retrieval; low on any benefit.
Sources used 4
-
Single-cell RNA sequencing reveals neutrophil differentiation-related genes for immunotherapy response prediction in colorectal cancer
Single-cell RNA sequencing of colorectal cancer reveals neutrophil differentiation–related genes that predict immunotherapy response and identifies Ivermectin as a potential adjunct therapeutic strategy.
DOI: 10.1186/s12885-025-15355-7 -
Old wine in new bottles: Drug repurposing in oncology
A comprehensive narrative review detailing how eight non-oncologic drugs (artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide) have demonstrated anticancer activity across in vitro, in vivo, and limited clinical contexts, outlining the…
DOI: 10.1016/j.ejphar.2019.172784 -
A field evaluation of anthelmintics for control of cyathostomes of horses in Brazil
This study evaluates the efficacy of ivermectin, piperazine citrate, and fenbendazole, both alone and in combination, for controlling cyathostome infections in horses in Brazil, revealing significant differences in treatment effectiveness and suggesting emerging resistance to ce…
DOI: 10.1016/0304-4017(91)90122-c -
Effect of the antiparasitic drugs fenbendazole and ivermectin on the soil nematode Pristionchus maupasi
This study investigates the ecotoxic effects of the antiparasitic drugs fenbendazole and ivermectin on the soil nematode Pristionchus maupasi, revealing that neither drug has acute toxic effects at naturally excreted concentrations in cattle dung.
DOI: 10.1016/j.vetpar.2004.06.003